AR and prostate carcinoma: These findings, together with the observation the TRPM8 modulators inhibit the proliferation of AR-expressing castrate resistant prostate cancer (CRPC) cells, while leaving unaffected the behavior of AR-negative PC cells, offer new insights into the knowledge of TRPM8 in PC pathogenesis and pave the way for novel promising strategies in clinical management of PC patients.